Events Details
Leinco Technologies and CellCarta Partner to Strengthen Proteomics Solutions for Drug Development
Wednesday, April 22, 2026
Leinco Technologies, a specialist in antibody and protein development, has entered into a strategic collaboration with CellCarta, a global provider of precision medicine laboratory services, to advance proteomics solutions for drug development. The partnership will support research in immuno-oncology and other targeted therapies.
The collaboration combines Leinco’s portfolio of high-quality antibodies, including those validated for tissue analysis methods such as immunohistochemistry, with CellCarta’s range of CPTAC antibodies used in Immuno-MRM assays. This integration is designed to provide researchers and clinicians with improved tools for biomarker discovery and clinical research.
CellCarta’s Immuno-MRM assays enable highly multiplexed and quantitative protein analysis, allowing accurate measurement of specific targets in clinical samples. These assays use antibodies validated to meet CPTAC standards and are suitable for a wide range of research stages, from early exploration to clinical trials.
By bringing together their respective capabilities, the two companies aim to improve the sensitivity and accuracy of proteomic analysis. This is expected to support the development of targeted therapies and personalised treatment approaches.
The combined offering will cater to both small-scale research and large-volume clinical use. Researchers can access smaller quantities for early-stage studies, while clinical laboratories can use larger volumes for routine testing, helping to bridge the gap between discovery and clinical application.
The partnership is intended to support drug development by enabling reliable protein measurement, identification of new biomarkers, and evaluation of treatment responses. These capabilities are expected to contribute to faster development of new therapies and improved outcomes in immuno-oncology.
Source: leinco.com
